Maximus Ranked #7 on the Financial Times’ List of The Americas’ Fastest Growing Companies 2026

In this episode of Global Economic Press, Alex Brady discusses the impressive rise of Maximus, a performance medicine telehealth company that has been ranked number seven on the Financial Times' list of The Americas' Fastest Growing Companies for 2026. The podcast delves into how Maximus is revolutionizing healthcare by offering cutting-edge clinical science and personalized treatment protocols through a fully online telehealth platform. Founded in 2020, Maximus initially launched with testosterone optimization protocols and has since expanded into GLP-1 weight loss treatments, hair regrowth solutions, and peptide therapies, including growth hormone releasing hormones. This growth highlights the increasing demand for performance medicine, which focuses on optimizing health outcomes proactively rather than treating symptoms reactively. Maximus's success is attributed to its direct-to-consumer telehealth model, which eliminates traditional barriers to accessing performance-focused treatments. Backed by prominent venture capital firms like Founders Fund and 8VC, Maximus has demonstrated sustained revenue growth from 2021 through 2024, showcasing a durable business model with strong client retention and expanding treatment protocols. Dr. Cameron Sepah, Founder and Chief Executive Officer of Maximus, emphasizes the company's mission to help individuals transcend their potential and perform at their peak. This recognition by the Financial Times validates the growing market for performance medicine, with Maximus leading the charge. For more information about Maximus and its innovative healthcare solutions, visit their website at Maximus.